Postpartum Hemorrhage (PPH) Treatment Market Size, Share, and Industry Analysis, By Drug (Oxytocin, Methylergonovine, Carboprost tromethamine, and Others), By Route of Administration (Oral and Parenteral), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and Regional Forecast, 2025-2032

The global postpartum hemorrhage (PPH) treatment market is witnessing significant growth due to the increasing incidence of postpartum complications across the globe. Postpartum hemorrhage (PPH) is a critical global health issue, recognized as the leading cause of maternal mortality worldwide.

• PPH accounts for over 20% of all maternal deaths, with estimates suggesting that around 70,000 women die annually due to the severe bleeding after childbirth.

The market growth is further driven by the increasing awareness of maternal health and rising governmental initiatives for the prevention of maternal deaths that is expected to increase the demand for its treatment and is anticipated to grow over the forecast period.

Postpartum Hemorrhage (PPH) Treatment Market Driver

Rising Incidence of Postpartum Hemorrhage (PPH) Treatment to Boost Market Growth

The postpartum hemorrhage (PPH) treatment market is significantly driven by the increasing prevalence of pregnancy-related complications, which elevates the risk of PPH.

• For instance, a study reported in January 2023, a prevalence of 0.73% in a tertiary care hospital, highlighting that uterine atony was the most common cause of PPH, accounting for about 79% of cases. Factors such as uterine atony, retained placenta, and conditions such as multiple pregnancies contribute to this rise, necessitating the effective treatment options.

Furthermore, the growing awareness of maternal health issues and governmental initiatives aimed at reducing maternal mortality rates are propelling the market.

To know how our report can help streamline your business, Speak to Analyst

A study published in February 2023 in Frontiers in Medicine reported a higher incidence of primary postpartum hemorrhage (PPH) among women aged 18-30. Conducted in Ethiopia with a sample size of 577 patients, the research is aimed to investigate the prevalence and related factors contributing to PPH.

Postpartum Hemorrhage (PPH) Treatment Market Restraint

Lack of Drug Availability Can Limit Market Growth

The postpartum hemorrhage (PPH) treatment market is significantly restrained by the lack of drug availability, particularly in the low- and middle-income countries (LMICs).

• This shortage often stems from fragmented supply chains, inadequate healthcare infrastructure, and inconsistent procurement processes that hinder access to essential medications such as oxytocin and misoprostol.

Postpartum Hemorrhage (PPH) Treatment Market Opportunity

Surging Awareness Regarding Postpartum Hemorrhage (PPH) to Provide Future Growth Opportunities

The developing regions are expected to offer lucrative opportunities for the market due to higher incidence of these condition in these regions. The rising awareness of PPH and the implementation of preventive measures, such as the use of uterotonic medications such as oxytocin and misoprostol is expected to enhance the market potential. Additionally, the advancements in drug delivery systems and the availability of innovative treatment options are expected to improve patient outcomes and drive the market expansion. Moreover, regulatory body initiatives is expected to offer new opportunities in the market.

• For instance, in March 2023, WHO launched the first roadmap to control PPH between 2023 and 2030. This roadmap outlines the goals and activities for research, normative work, and implementation.

Segmentation

Key Insights

The report covers the following key insights:

• Incidence of PPH, By Key Countries, 2023
• Key Industry Development (Acquisitions, Mergers, Partnerships)
• Pipeline Analysis, By Key Players
• Impact of COVID-19 on the Market

Analysis by Drug

Based on drug, the market is divided into oxytocin, methylergonovine, carboprost tromethamine, and others.

The carboprost tromethamine segment holds a significant market share, as they are widely used in the treatment due to its effectiveness. The wide availability and cost-effectiveness of this drug, as compared to the other alternatives and increasing number of product launches is increasing the penetration of these drugs across the globe. 

• In July Dr. Reddy's Laboratories announced the launch of Carboprost Tromethamine Injection USP, 250 mcg/mL (1mL) Single-dose Vial in the U.S. market. Such launches are expected to boost the segment growth over the projected period.

Analysis by Route of Administration

By route of administration, the market is fragmented into oral and parenteral.

The parenteral segment held a substantial revenue share in the market. The growth can be attributed to their advantages such as a rapid onset and precise control over dosing, making it ideal for emergency situations where immediate uterine contraction is necessary. Additionally, the increasing number of drug approvals are expected to fuel the segment growth.

• In February 2023, Caplin Point Laboratories Limited received the U.S. Food and Drug Administration (USFDA) for its Carboprost Tromethamine Injection USP, 250 mcg/mL Single-dose Vials, a generic therapeutic equivalent version of HEMABATE Injection, of Pfizer Inc.

Analysis by Distribution Channel

Based on distribution channel, the market is divided into hospital pharmacies, retail pharmacies, and online pharmacies.

The hospital pharmacies accounted for significant share in the market. Hospital pharmacies are the primary distribution channel for the PPH drugs and provide immediate access to medications during emergencies, which is critical for managing PPH effectively. Additionally, the increasing volume of childbirths in hospital settings and the necessity for prompt treatment options contribute to the dominance of this channel.

• According to the American Medical Association, in June 2023, childbirth remains the leading reason for hospitalization among women, with over 11.6 million delivery-related hospitalizations analyzed between 2008 and 2021 in the U.S. Such higher hospitalization rates and demand for immediate access of these drugs are expected to fuel the segment growth.

Regional Analysis

To gain extensive insights into the market, Download for Customization

By region, the market has been studied across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

North America accounted for the largest share of the market in 2023. The region’s advancements in the treatment modalities also contributes significantly to the market expansion. Additionally, advanced healthcare facilities, high delivery rates in hospitals, and rising awareness about maternal health issues is driving the regional growth.

Europe also accounts for a moderate share for the PPH treatment market. This growth is attributed to favorable government policies and a high incidence of conditions that elevate the risk of PPH, such as multiple pregnancies and uterine fibromas in the region can boost the market growth during the forecast period.

In the Middle East and Africa, the market is expected to grow due to significant challenges related to maternal health that increases the demand for PPH drugs to control maternal death.

• For instance, as per WHO report in March 2023, over 85% of deaths from postpartum hemorrhage (PPH) occur in sub-Saharan Africa and South Asia and it is leading cause of maternal death. These factors are expected to boost the demand for PPH drugs.

Key Players Covered

The global postpartum hemorrhage (PPH) treatment market is fragmented with several players, ranging from emerging to established players. The report includes the profiles of the following key players:

• Pfizer Inc. (U.S.)
• Novartis AG (Switzerland)
• Lupin (India)
• Amneal Pharmaceuticals LLC. (U.S.)
• Caplin Point Laboratories Ltd. (India)
• Reddy’s Laboratories Ltd. (India)
• Sun Pharmaceutical Industries Ltd. (India)

Key Industry Developments

• In November 2024, Insud Pharma received a fund of USD 2.7 million from Bill & Melinda Gates Foundation to conduct a Phase II clinical trial to determine the optimal dose of sublingual oxytocin to prevent PPH.
• In July 2023, Endo International plc and Premier, Inc., announced that Endo's Par Sterile Products business will supply Pitocin (oxytocin injection, USP) vials through Premier's ProvideGx and PremierProRx programs.